479
REMARKABLE DIFFERENCE IN RE-TREATMENT RESPONSE IN
PATIENTS WITH DIFFERENT HBsAg/ALT KINETICS DURING
OFF-NUC HEPATITIS FLARE
Wen-Juei Jeng1,2, Yen-Chun Liu1,2, Rong-Nan Chien1,2 and
Yun-Fan Liaw3,4, (1)College of Medicine, Chang Gung
University, Taiwan, (2)Department of Gastroenterology and
Hepatology, Chang Gung Memorial Hospital, Linkou Branch,
Taiwan, (3)Liver Research Unit, Chang Gung Memorial
Hospital, Linkou Branch, (4)College of Medicine, Chang Gung
University
Background: Off-Nuc hepatitis flare (AE: ALT > 5X ULN) with
deceasing qHBsAg may reflect successful immune clearance
whereas those with increasing qHBsAg reflect ineffective
immune response Aim: To investigate whether AE with
different pretherapy HBsAg/ALT kinetics showed different retreatment
response Methods: HBeAg-negative off-Nuc AE
with qHBsAg at ≥3 time points (pre-flare, during flare, months
6 and/or 12 of re-treatment) were studied Pre-treatment
ALT, HBV DNA and qHBsAg levels, on-treatment start to
ALT normalization, undetectable HBV DNA, the presence of
“rapid HBsAg decline” (HBsAg decline > 0.5log10 in 6 months
or > 1 log10IU/ml in 12 months) during re-treatment were
compared between patients with different pretherapy HBsAg/
ALT kinetics Logistic regression was applied Results: Of
202 patients with off-Nuc flare, 18.8% showed decreasing
qHBsAg (group I) and 81 2% showed increasing qHBsAg
(group II) The two groups were comparable in demographic
features, previous treatment and consolidation duration, but
higher end of treatment (EOT) qHBsAg in group I (median:
2 9 vs 2 7 Log10IU/ml, P=0 001) At the start of re-treatment,
group I patients had lower ALT level (median: 251 vs. 388
U/L, P=0.0001), lower HBV DNA level (5.8 vs. 6.7 log10IU/
ml, P=0 0002) and lower qHBsAg level (2 7 vs 3 4 log10IU/
ml, P<0 0001) During re-treatment, “rapid HBsAg decline”
occurred in 73 2% of group II vs 7 9% of group I patients
(P<0 0001), median qHBsAg decline by month 12 was -0 07
log10IU/ml vs -0 91 log10IU/ml (Figure) Higher ALT level
(³ 10X ULN vs 5-10X ULN, aOR: 2.8 (1.3-6.2), P=0.008),
higher HBV DNA level [>7 log10IU/ml: aOR: 3.5 (1.2-10.2),
P=0.219], higher qHBsAg level [aOR: 4.1 (1.8-9.5), P=0.003]
at start of re-treatment and group II patients [vs. group I:
aOR: 19.6 (4.8-80.7), P<0.001] were independent factors for
“rapid HBsAg decline” Remarkably, 78 9%, 13 2% of group
I vs 26 2%, 0% of group II patients showed stationary and
increased qHBsAg level respectively at month 12 (P<0 0001)
Conclusion: Patients with decreasing qHBsAg during off-
Nuc AE showed minimal decline or even increasing qHBsAg
during re-treatment Perhaps re-treatment in such patients
is too soon that halt endogenous immune control Further
observation is necessary to decide the necessity or timing of
re-treatment. 作者: StephenW 时间: 2019-10-28 16:44